Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12.
We examined the safety and immunogenicity of a human leukocyte antigen-based HIV envelope polyvalent synthetic peptide vaccine, C4-V3, alone and in combination with subcutaneous IL-12 in nine HIV-infected patients. Lymphocyte proliferative responses increased threefold or more to all four peptides at two consecutive post-immunization timepoints for four individuals. Three responders had received IL-12, suggesting a possible adjuvant effect of IL-12. Transient mild injection site reactions (7/9) and systemic symptoms (3/9) occurred.
Sha, B.E.; Onorato, M.; Bartlett, J.A.; Bosch, R.J.; Aga, E.; Nokta, M.; Adams, E.M.; Li, X.D.; Eldridge, J.; Pollard, R.B. Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS (2004) 18 (8) 1203-1216.